DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With H… (NCT04337450) | Clinical Trial Compass
Active — Not RecruitingPhase 2/3
DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old
South Africa, Spain, Thailand386 participantsStarted 2022-04-22
Plain-language summary
This study aims to find out whether treating children and young people living with HIV with two anti HIV medicines, dolutegravir and lamivudine, is safe and as effective as the three-medicine anti-HIV treatments currently used in routine practice.
Who can participate
Age range2 Years – 15 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. HIV-1 infected children who are virologically suppressed for at least the last 6 months prior to enrolment
✓. Aged 2 to \<15 years old
✓. Weight 6 kg or higher
✓. Children on the same triple-drug PI/r, NNRTI or INSTI containing ART regimen for at least 3 months
✓. Girls who have reached menarche must have a negative pregnancy test at screening and randomisation
✓. Girls who are sexually active must be willing to adhere to highly effective methods of contraception
✓. A parent or legal guardian is willing and able to give informed consent on behalf of the child as per national legislation and willing to adhere to the protocol
✓. Participant is willing to give informed assent if the trial site clinician deems them old enough and able to understand the age-appropriate information about participation in the study
Exclusion criteria
✕. Any previous switch in ART regimen for virological, immunological or clinical treatment failure
✕. Any changes in ART in the last 6 months for reasons other than due to child's growth, drug stock-outs, changes in country guidelines and treatment simplification
✕. Evidence of previous resistance to 3TC or INSTI
✕
What they're measuring
1
Proportion of children with confirmed viral rebound (defined as the first of two consecutive HIV-1 RNA ≥50c/mL) by week 96
. Any prior use of regimens consisting of single or dual NRTIs with the exception of a course of zidovudine for PMTCT
✕. Known allergy or contraindications to dolutegravir or lamivudine
✕. Diagnosis of tuberculosis and on anti-tuberculosis treatment; children can be enrolled after successful tuberculosis treatment
✕. Treatment of co-morbidities with drugs which have significant interactions with antiretroviral treatment, requiring dose adjustment of the study drugs (children can be enrolled after the illness resolves)
✕. Randomisation visit more than 12 weeks after the most recent screening visit